Annovis Bio, Inc. 8-K

What Happened

• Annovis Bio, Inc. (ANVS) filed a Form 8-K on February 12, 2026 to disclose a press release under Item 7.01 (Regulation FD Disclosure). The press release was furnished as Exhibit 99.1 to the filing.
• The filing also references an Inline XBRL cover page / interactive data file (Exhibit 104). No other Item disclosures (e.g., earnings, executive changes, mergers) are reported in this 8-K.

Key Details

• Filing date: February 12, 2026 (Form 8-K).
• Item disclosed: 7.01 — Regulation FD Disclosure (press release furnished).
• Exhibits included: Exhibit 99.1 (press release) and Exhibit 104 (Cover Page Interactive Data File).
• The 8-K does not report Item 2.02 (earnings), Item 5.02 (executive changes), Item 1.01 (merger), or Item 1.03 (bankruptcy).

Why It Matters

• This 8-K signals that material company information was publicly released via a press release; investors should read Exhibit 99.1 to learn the specific news and any impact on operations or outlook.
• Because the filing does not include earnings, revenue figures, or management changes, investors should not assume financial results or executive actions from this filing alone — check the press release and subsequent SEC filings for substantive financial or corporate updates.